Application of triglyceride compound to preparation of composition for treating and improving pulmonary fibrosis
Reversing epithelial-mesenchymal transformation by triglyceride compounds solves the problem of pulmonary fibrosis treatment, significantly alleviates the symptoms of pulmonary fibrosis, and provides a new treatment strategy to improve lung function and weight problems.
Patent Information
- Application Number
- CN202411085467.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-19
AI Technical Summary
There is a lack of effective treatment for pulmonary fibrosis, and existing drugs have limited effectiveness in improving survival prognosis, and drugs targeting the regulation of epithelial-mesenchymal transformation (EMT) molecules are ineffective, resulting in treatment difficulties.
The triglyceride compounds or pharmaceutically acceptable salts thereof are used to significantly alleviate the symptoms of pulmonary fibrosis by reversing epithelial-mesenchymal transformation, and are used to prepare compositions for treating and improving pulmonary fibrosis.
Triglycerides can reverse epithelial-mesenchymal transformation, significantly reduce symptoms of pulmonary fibrosis, improve lung function and weight loss, and provide a new strategy for treating pulmonary fibrosis.
Smart Images

Figure CN118976018A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicine, and in particular, to the use of triglyceride compounds or pharmaceutically acceptable salts thereof in preparing a composition for treating and improving pulmonary fibrosis. Background Art
[0002] Pulmonary fibrosis (PF) includes a series of chronic, progressive, and fatal lung diseases. Because they mainly affect the lung interstitium, these diseases are also called interstitial lung diseases (ILDs). Many diseases can lead to pulmonary fibrosis. Among them, idiopathic pulmonary fibrosis (IPF) is the most common form of pulmonary fibrosis, which often occurs in middle-aged and elderly male patients. Inflammation and fibrosis of the lung interstitium in patients with pulmonary fibrosis lead to pulmonary gas exchange disorders. Patients usually show non-specific symptoms such as dry cough and exertional dyspnea in the early stage. As lung function continues to deteriorate, the patient's dyspnea symptoms will progressively worsen, and respiratory failure and even death will inevitably occur. Pulmonary fibrosis seriously affects the quality of life of patients and has a poor prognosis. For example, IPF patients have a significantly higher risk of lung cancer, pulmonary hypertension, and pulmonary embolism than the general population, and the median survival time is only 2-4 years. It is estimated that the incidence of pulmonary fibrosis is 1-31.5 per 100,000 person-years and the prevalence is 6.3-71 per 100,000 person-years. Against the backdrop of an aging global population, the incidence and prevalence of pulmonary fibrosis are increasing year by year, and the socioeconomic burden it brings will continue to increase. Lung transplantation can improve the life expectancy of PF patients, but it is difficult to promote due to the limited donor sources, high surgical difficulty, complex postoperative treatment and improvement, and high costs. Although the two widely used anti-fibrotic drugs (pirfenidone and nintedanib) in clinical practice can delay the decline of lung function in patients with pulmonary fibrosis to a certain extent, they have limited effects in improving survival prognosis and there is a problem of drug intolerance. Therefore, there is still a lack of effective and feasible treatment and improvement methods for pulmonary fibrosis.
[0003] The molecular mechanism of pulmonary fibrosis is still unclear. The mainstream view is that the key initiating factor of pulmonary fibrosis is the dysregulated repair of repeatedly damaged alveolar epithelial cells, and epithelial-mesenchymal transition (EMT), as the main tissue damage repair pathway, plays an important role in it. A large amount of experimental evidence shows that in the context of pulmonary fibrosis, alveolar epithelial cells undergo EMT, and reversing lung tissue EMT can alleviate pulmonary fibrosis. However, many drugs that target and regulate EMT molecules have been proven to be ineffective in clinical evaluations. Therefore, further in-depth exploration of the molecular mechanism of regulating EMT is of great significance for establishing more effective drug targets and achieving precise treatment and improvement of pulmonary fibrosis.
[0004] Studies have shown that lipid disorders are involved in the development of pulmonary fibrosis. Some observational studies have found that IPF patients have lipid metabolism disorders and are associated with a higher mortality rate. However, previous studies have mainly focused on lipid types such as cholesterol, fatty acids, and phospholipids.
[0005] Triglycerides are widely found in nature. Their chemical structure is formed by the esterification reaction of one glycerol molecule and three fatty acids. The physicochemical properties of triglycerides vary according to the type and chain length of the fatty acids they contain. Based on the differences in physicochemical properties, they are widely used in the food industry, biomedicine, and other chemical fields. However, there are no reports on the use of triglyceride compounds in the treatment and improvement of pulmonary fibrosis.
[0006] After continuous exploration, the inventors confirmed for the first time the causal genetic relationship between plasma triglyceride levels and pulmonary fibrosis, that is, people with lower plasma triglycerides have a higher genetic susceptibility to pulmonary fibrosis compared with normal people. Based on the research results, the inventors proposed that triglyceride supplementation may be an effective strategy for treating and improving pulmonary fibrosis. In addition, cell and animal experiments have verified that triglyceride compounds or pharmaceutically acceptable salts thereof have an amazing ability to reverse epithelial-mesenchymal transition and significantly reduce the symptoms of pulmonary fibrosis in mice. Summary of the invention
[0007] The technical problem to be solved by the present invention is to provide a new way to effectively treat and improve pulmonary fibrosis. The pulmonary fibrosis is preferably idiopathic pulmonary fibrosis. Specifically, the epithelial-mesenchymal transition is reversed, the weight loss and decreased lung function caused by pulmonary fibrosis are improved, and the symptoms of pulmonary fibrosis are significantly alleviated.
[0008] The present invention provides a use of a triglyceride compound or a pharmaceutically acceptable salt thereof for preparing a composition for treating and improving pulmonary fibrosis, wherein the triglyceride compound is a compound in which the content of the compound represented by formula I is more than 90%.
[0009] In the formula, R1, R2 and R3 are each independently selected from the following groups: C2-C 30 Alkyl, C2-C 30 Alkenyl.
[0010]
[0011] According to an embodiment of the present invention, R1, R2 and R3 are each independently selected from C6-C 22 Monounsaturated alkenyl.
[0012] According to an embodiment of the present invention, R1, R2 and R3 are each independently selected from C 14 -C22 Monounsaturated alkenyl.
[0013] According to an embodiment of the present invention, R1, R2 and R3 are each independently selected from C 16 -C 20 Monounsaturated alkenyl.
[0014] According to an embodiment of the present invention, R1, R2 and R3 are each independently selected from C 17 -C 19 Monounsaturated alkenyl.
[0015] According to an embodiment of the present invention, the compound represented by Formula I comprises triolein.
[0016] According to an embodiment of the present invention, the triglyceride compound is derived from naturally occurring oil, naturally occurring fat, semi-synthetic triglyceride or synthetic triglyceride.
[0017] According to an embodiment of the present invention, the composition includes: a pharmaceutical composition, a health product composition, a food composition, or a dietary supplement composition.
[0018] According to an embodiment of the present invention, the composition can be administered orally, intravenously, subcutaneously, intramuscularly, nasally, through bronchoscopy or by aerosol inhalation.
[0019] According to an embodiment of the present invention, the composition is used to reverse epithelial-mesenchymal transition.
[0020] According to an embodiment of the present invention, the composition is used to alleviate fibrosis symptoms.
[0021] According to an embodiment of the present invention, the composition is used to improve weight loss or decreased lung function caused by pulmonary fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1The effect of triolein on the EMT phenotype of A549 cells induced by transforming growth factor-β1 (TGF-β1), wherein: Part A is the protein expression levels of E-cadherin, vimentin, α-smooth muscle actin (α-SMA) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in each group of cells; Part B is the ratio of the gray value of Vimentin to the gray value of GAPDH in Part A, and the results are expressed as "mean ± standard deviation"; Part C is the ratio of the gray value of α-SMA to the gray value of GAPDH in Part A, and the results are expressed as "mean ± standard deviation"; Part D is the immunofluorescence images of Vimentin (green) and α-SMA (red) in each group of cells (magnification 100×, scale bar shows 50μm), and the cell nucleus is stained with 4',6-diamidino-2-phenylindole (DAPI) (blue); the average number of Vimentin-positive or α-SMA-positive cells is quantified, and the results are expressed as "mean ± standard deviation". (*p value <0.05, **p value <0.01, ***p value <0.001, ****p value <0.0001, ns, no statistically significant difference). TGF-β1: transforming growth factor beta 1; Triolein: triolein; E-cadherin: E-cadherin; Vimentin: vimentin; α-SMA: α-smooth muscle actin; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; DAPI: 4',6-diamidino-2-phenylindole (DAPI).
[0023] Figure 2The effects of triolein on body weight, lung function and pulmonary fibrosis in mice induced by bleomycin (BLM), wherein: Part A shows the changes in body weight of mice in each group, and the asterisk indicates the difference between the BLM group and the BLM+triolein group, and the results are expressed as "mean ± standard error"; Part B shows the enhanced pause (Penh) of mice in each group, and the results are expressed as "mean ± standard deviation"; Part C shows the Ashcroft score of lung tissue sections of mice in each group, and the results are expressed as "mean ± standard deviation"; Part D shows Masson staining of paraffin sections of lung tissue of mice in each group (magnification 100×, scale bar shows 100 μm); Parts E and F show the mRNA expression levels of E-cadherin 1 (Cdh1) gene (E) and vimentin (Vim) gene (F) in lung tissue of mice in each group, and the results are expressed as "mean ± standard deviation". (*p value < 0.05, **p value < 0.01, ***p value < 0.001, ****p value < 0.0001, ns, no statistically significant difference). BLM: Bleomycin; Cdh1: Cadherin 1; Vim: Vimentin.
[0024] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention so that it can be implemented in accordance with the contents of the specification, and in order to make the above and other purposes, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are listed below. DETAILED DESCRIPTION
[0025] After unremitting research, the present invention proposes for the first time the use of triglyceride compounds or pharmaceutically acceptable salts thereof as active ingredients, especially as the only active ingredient, for preparing a composition for treating and improving pulmonary fibrosis, especially idiopathic pulmonary fibrosis.
[0026] Active ingredient triglyceride
[0027] Triglyceride is an ester formed by the reaction of all three hydroxyl groups of the glycerol part with a fatty (carboxylic) acid. The fatty acid may contain a saturated or unsaturated chain fatty acid. The triglyceride compound of the present invention is a compound having a content of more than 90% of the compound shown in formula I.
[0028]
[0029] In the formula, R1, R2 and R3 are each independently selected from the following groups: C2-C 30 Alkyl, C2-C 30 Alkenyl.
[0030] According to an embodiment of the present invention, R1, R2 and R3 are preferably each independently selected from C6-C 22 Alkyl or C6-C 22 Alkenyl.
[0031] According to an embodiment of the present invention, R1, R2 and R3 are preferably each independently selected from C 14 -C 22 Monounsaturated alkenyl.
[0032] According to an embodiment of the present invention, R1, R2 and R3 are preferably each independently selected from C 16 -C 20 Monounsaturated alkenyl.
[0033] According to an embodiment of the present invention, R1, R2 and R3 are preferably each independently selected from C 17 -C 19 Monounsaturated alkenyl.
[0034] The fatty acids forming the triglyceride compounds of the present invention include saturated or unsaturated chain fatty acids, and the number of carbon atoms constituting the saturated or unsaturated chain fatty acids can range from 2 carbon atoms to a maximum of 30 carbon atoms, preferably the number of carbon atoms is 6-22, more preferably the number of carbon atoms is 14-22, more preferably the number of carbon atoms is 16-20, and most preferably the number of carbon atoms is 17-19.
[0035] The fatty acid is preferably an unsaturated chain fatty acid, more preferably a monounsaturated chain fatty acid. The carbon number of the unsaturated chain fatty acid or the monounsaturated chain fatty acid can range from 2 carbon atoms to a maximum of 30 carbon atoms, preferably 6-22 carbon atoms, more preferably 14-22 carbon atoms, more preferably 16-20 carbon atoms, and most preferably 17-19 carbon atoms.
[0036] Saturated fatty acids include acetic acid (2), propionic acid (3), butyric acid (4), valeric acid (5), caproic acid (6), heptanoic acid (7), octanoic acid (8), nonanoic acid (9), decanoic acid (10), undecanoic acid (11), lauric acid (12), tridecanoic acid (13), myristic acid (14), pentadecanoic acid (15), palmitic acid (16), margarine acid (17), stearic acid (18), nonadecanoic acid (19), arachidic acid (20), heneicosanoic acid (21), anisopic acid (22), tricarboxylic acid (23), tetracosanoic acid (24), pentacarboxylic acid (25), hexacosanoic acid (26), heptacosanoic acid (27), montanylic acid (28), azelaic acid (29) and melissic acid (30), where the number in brackets is the number of carbon atoms in the fatty acid molecule.
[0037] Examples of unsaturated fatty acids include crotonic acid (4:1), caprylic acid (8:1), capric acid (10:1), decaenoic acid (10:2), lauric acid (12:1), lauric acid (12:2), myristoleic acid (14:1), myristoleic acid (14:2), myristoleic acid (14:3), palmitoleic acid (16:3), hexadecatrienoic acid (16:3), palmitotetraenoic acid (16:4), α-linolenic acid (18:3), stearic acid (18:4), 11,14,17-eicosatrienoic acid (20:3), eicosatetraenoic acid (20:4), eicosapentaenoic acid (20:4), and 11,14,17-eicosatrienoic acid (20:3). Acid (20:5), eicosapentaenoic acid (21:5), herringic acid (22:5), docosahexaenoic acid (22:6), 9,12,15,18,21-eicosapentaenoic acid (24:5), myristic acid (14:1), palmitoleic acid (16:1), α-eleostearic acid (18:3), β-eleostearic acid (trans-18:3), punicic acid (18:3), 7,10,13-octadecatrienoic acid (18:3), 9,12,15-eicosatrienoic acid (20:3), β-eicosatetraenoic acid (20:4), tetradecenoic acid (14:1), 12-octadecatrienoic acid (18:3), linoleic acid (18:1), linoleic acid (18:2), linoleic acid (trans-18:2), γ-linolenic acid (18:3), calendula acid (18:3), pinolenic acid (18:3), 11,14-eicosadienoic acid (20:2), dihomolinoleic acid (20:2), dihomo-γ-linolenic acid (20:3), arachidonic acid (20:4), docosenoic acid (22:2), adrenaline (22:4), osbornenic acid (22:5), tetracosadetraenoic acid (24:4), tetracospentaenoic acid (24:5), 5-dodecenoic acid (12:1), 7-tetradecenoic acid ( The following are the fatty acids: palmitoleic acid (14:1), palmitoleic acid (16:1), vaccenic acid (18:1), hyaluronic acid (16:1), oleic acid (18:1), elaidic acid (trans-18:1), oleic acid (20:1), 8,11-eicosadienoic acid (20:2), erucic acid (22:1), oxime acid (24:1), mead acid (20:3), nicotinic acid (16:1), gadolinic acid (20:1), 4-hexadecenoic acid (16:1), petroselinic acid (18:1) and eicosenoic acid (20:1), where the numbers in brackets are the number of carbon atoms and the number of unsaturated double bonds in the fatty acid molecule, respectively.
[0038] Preferred fatty acids include caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, ricinoleic acid, linoleic acid, linolenic acid, eicosenoic acid, anisopic acid, erucic acid and the like.
[0039] The triglycerides may be naturally occurring oils or fats, may be semi-synthetic or may be synthetic.
[0040] Naturally occurring oils or fats may be obtained from animals, or more preferably from plant sources, such as seeds, grains or fruits.
[0041] The major component of naturally occurring vegetable oils is triglycerides, which are mixtures of glycerides having different fatty acid chain lengths. Naturally occurring pharmaceutically acceptable oils belonging to this class include sunflower seed oil, soybean oil, corn oil, grape seed oil, rapeseed oil, sesame oil, almond oil, apricot kernel oil, cottonseed oil, palm kernel oil, castor oil, olive oil, palm oil and coconut oil.
[0042] When used in the dosage forms of the present invention, naturally occurring oils should be of food or pharmaceutical grade and should therefore preferably be refined after extraction from their natural sources. The refining process can be accomplished using techniques well known to those skilled in the art.
[0043] Preferred vegetable oils include one or more of sesame oil, corn oil, palm kernel oil, coconut oil or soybean oil.
[0044] Semisynthetic and synthetic triglycerides can be prepared using techniques well known to those skilled in the art, such as isolation, transesterification, lipolysis and transesterification (glycerolysis).
[0045] Regardless of the source of the triglyceride compound, the content of the compound of formula I is preferably above 90%, more preferably above 95%, and even more preferably above 99%. It is most preferred that the triglyceride compound contains only the compound of formula I (excluding impurities).
[0046] Composition and use thereof
[0047] The composition of the triglyceride compound (the content of the compound of formula I is 90% by weight or more) or a pharmaceutically acceptable salt thereof as an active ingredient of the present invention can be used to treat and improve pulmonary fibrosis.
[0048] The compositions of the present invention include: pharmaceutical compositions, food compositions, health care compositions, dietary supplements, beverage compositions, and the like.
[0049] The composition of the present invention comprises a triglyceride compound (the compound of formula I is the main component) or a pharmaceutically acceptable salt thereof and an acceptable excipient or carrier within a safe and effective amount. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly treat and improve the condition without causing serious side effects. The dosage and number of administrations of the present invention can be determined by factors such as the severity of the disease, the route of administration, the patient's age, sex, weight, and health status. The pharmaceutical composition is a single dose administered pharmaceutically.
[0050] "Acceptable excipients or carriers" refer to: adhesives, fillers, disintegrants, lubricants in tablets; matrix parts in semi-solid ointments and creams; excipients such as preservatives, antioxidants, flavoring agents, fragrances, cosolvents, emulsifiers, solubilizers, osmotic pressure regulators, colorants, etc. in liquid preparations; biopolymers derived from animals, plants and microorganisms, carrier materials with good biocompatibility, biodegradability and renewability, such as carrier materials that form microcapsules, nanoparticles, liposomes, etc. The carrier or excipient must be of sufficient purity and sufficiently low toxicity.
[0051] The composition of the present invention can be administered orally, intravenously, subcutaneously, intramuscularly, nasally, through bronchoscopy or by aerosol inhalation.
[0052] Solid preparations such as tablets, sugar pills, capsules, pills and granules. In addition, the release of the active substance in this composition can be released in a certain part of the digestive tract in a delayed manner. If necessary, the active compound can also be formed into a microcapsule form with one or more of the above-mentioned excipients.
[0053] Liquid dosage forms include emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances. In addition to these inert diluents, the composition may also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and spices.
[0054] Compositions for injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0055] The dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays and aerosol inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required if necessary.
[0056] Example
[0057] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are weight percentages and weight parts. If not specifically mentioned, the raw materials used in the following examples are all commercially available products, and their quality meets national standards.
[0058] Example 1: Triglyceride compounds can effectively reverse the EMT phenotype induced by transforming growth factor β1 (TGFβ1) in A549 cells.
[0059] (1) Construction of TGFβ1-induced EMT model of alveolar epithelial cells and treatment with triglyceride supplement triolein
[0060] It should be noted that the source of the triolein is not particularly limited and can be purchased through conventional commercial channels. For example, the triolein used in this embodiment is purchased from Triolein of Selleck Company.
[0061] A549 cells were selected and treated with TGFβ110ng / mL for 48 hours to induce EMT in the cells. The cells were treated accordingly according to the following groups:
[0062] ①Control group: no treatment;
[0063] ②TGFβ1 group: treated with TGFβ1 10 ng / mL;
[0064] ③TGFβ1+triolein group: The mice were pretreated with different concentrations of triolein (10, 20, 30, 40 μM) for 1 hour and then co-treated with TGFβ1 10 ng / mL.
[0065] (2) Protein expression of cell EMT indicators
[0066] After 48 hours of treatment, cells in each group were collected to extract proteins, and WB was performed to detect the protein expression of EMT indicators E-cadherin, vimentin, and α-smooth muscle actin (α-SMA). Figure 1 Parts A, B, and C of the .
[0067] (3) Immunofluorescence staining of cell EMT indicators
[0068] A control group, a TGFβ1 group (TGFβ1 10 ng / mL), and a TGFβ1+triolein group (triolein 30 μM pretreatment for 1 hour and then co-treatment with TGFβ1 10 ng / mL) were set up. After 48 hours of the above treatment, cells in each group were subjected to cell immunofluorescence to show the expression of mesenchymal cell markers (Vimentin, α-SMA) and cell morphology changes. The structure is shown in Figure 1 Section D of the .
[0069] (4) Results analysis
[0070] like Figure 1 As shown in the figure, TGFβ1 treatment can induce EMT phenotype in A549 cells, that is, the expression of epithelial cell marker E-cadherin is reduced, the expression of mesenchymal cell markers Vimentin and α-SMA is increased, and the cell appearance changes from cobblestone epithelial cell morphology to spindle-shaped mesenchymal cell morphology; after adding triglyceride supplement trioleylglycerol treatment, the expression of E-cadherin in cells did not change significantly, but the expression of Vimentin and α-SMA was significantly reduced (most significantly under the condition of 30μM concentration treatment), and the cell appearance returned to cobblestone epithelial cell morphology. This suggests that triglyceride compounds can effectively reverse the EMT phenotype induced by TGFβ1 in A549 cells.
[0071] Example 2: Triglyceride compounds can effectively improve the body weight, lung function, lung fibrosis lesions and lung tissue EMT expression of mice with bleomycin (BLM)-induced pulmonary fibrosis.
[0072] (1) Construction of BLM-induced pulmonary fibrosis mouse model and treatment with triglyceride supplement triolein
[0073] BLM solution was prepared using sterile phosphate buffered saline (PBS). Eighteen SPF male C57BL / 6 mice aged 6-8 weeks were selected, and 12 mice were randomly selected. A single dose of BLM (2 mg / kg) was orally instilled into the trachea on day 0 to induce lung fibrosis in mice; the other 6 mice were used as the control group, and an equal volume of sterile PBS was instilled into the trachea. Starting from the 7th day after bleomycin modeling, each group of mice was treated accordingly according to the following scheme:
[0074] ① Control group: n=6, no treatment;
[0075] ②BLM group: n = 6, no treatment;
[0076] ③ BLM+triolein group: n=6, intraperitoneal injection of triolein (25 mg / kg, once a day, for 14 days).
[0077] All mice were tested for lung function using a non-invasive whole body plethysmography instrument (EMKA, France) on day 21. The main lung function index observed in the present invention was enhanced respiratory interval (Penh). The mice were then killed and lung tissues were collected for subsequent testing.
[0078] (2) Mouse weight monitoring
[0079] During the experiment, the body weight of mice in each group was monitored and statistical analysis was performed.
[0080] (3) Masson staining of mouse lung tissue sections
[0081] Mouse lung tissues were collected and fixed in 4% paraformaldehyde for 24 hours, then embedded in paraffin and sliced. The slices were stained with Masson's staining to evaluate the collagen deposition and severity of fibrosis in lung tissues.
[0082] The Ashcroft scoring criteria for lung tissue sections of mice in each group are as follows:
[0083]
[0084] (4) mRNA expression of EMT indicators in mouse lung tissue
[0085] Mouse lung tissues were collected, tissue RNA was extracted by Trizol method and reverse transcribed, and the mRNA expression of EMT indicators cadherin 1 (Cdh1) and vimentin (Vim) genes was analyzed by RT-qPCR.
[0086] The upstream primers and downstream primers of Cdh1, Vim and Gapdh (used to indicate the expression level of the target gene relative to the internal reference) used as the internal reference gene were designed and synthesized by Guangzhou Tianyi Huiyuan Gene Technology Co., Ltd., as shown in Table 1 below.
[0087] Table 1 Primer sequences
[0088] Gene Upstream primer Downstream primer Cdh1 CAGTTCCGAGGTCTACACCTT TGAATCGGGAGTCTTCCGAAAA Vim CGTCCACACGCACCTACAG GGGGGATGAGGAATAGAGGCT Gapdh TGGCCTTCCGTGTTCCTAC GAGTTGCTGTTGAAGTCGCA
[0089] (5) Results analysis
[0090] like Figure 2 As shown in the results, compared with the control group, the mice in the BLM treatment group had significantly reduced body weight, significantly increased airway resistance Penh, obvious collagen deposition and fibrosis in the lung tissue, decreased Cdh1 expression in the lung tissue, and increased Vim expression. Compared with the mice in the BLM group, the mice in the BLM+triolein group had faster weight recovery, significantly reduced airway resistance Penh, significantly reduced collagen deposition and fibrotic lesions in the lung tissue, and significantly reduced Vim expression in the lung tissue. The above results indicate that triglyceride compounds can effectively treat and improve pulmonary fibrosis.
[0091] In summary, the present invention uses the TGF-β1-induced A549 cell model and the BLM-induced pulmonary fibrosis mouse model as examples for research, and treats the cells and mice with the triglyceride supplement triolein. In the TGF-β1-induced A549 cell model, the EMT phenotype of cells treated with triolein was reversed. In the BLM-induced pulmonary fibrosis mouse model, compared with the BLM group, the BLM mice treated with triolein recovered faster, had significantly reduced airway resistance, significantly alleviated pulmonary fibrosis lesions, and significantly reduced the expression of Vimentin, a mesenchymal cell marker in lung tissue.
[0092] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form; any technician familiar with the art can make many possible changes and modifications to the technical solution of the present invention by using the above disclosed methods and technical contents without departing from the scope of the technical solution of the present invention, or modify it into an equivalent embodiment of equivalent changes. Therefore, any simple modification, equivalent replacement, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still falls within the scope of protection of the technical solution of the present invention.
[0093] Industrial Availability
[0094] The present invention provides the use of triglyceride compounds or pharmaceutically acceptable salts thereof for preparing a composition for treating and improving pulmonary fibrosis. The triglyceride compounds or pharmaceutically acceptable salts thereof can be used as a new solution for treating pulmonary fibrosis. The present invention has extremely broad prospects in the pharmaceutical industry.
Claims
1. A use of a triglyceride compound or a pharmaceutically acceptable salt thereof for preparing a composition for treating or improving pulmonary fibrosis, wherein the triglyceride compound is a compound having a content of more than 90% of the compound represented by formula I, In the formula, R1, R2 and R3 are each independently selected from: C2-C 30 Alkyl, C2-C 30 Alkenyl.
2. The use according to claim 1, wherein R1, R2 and R3 are each independently selected from C6-C 22 Monounsaturated alkenyl.
3. The use according to claim 1, wherein R1, R2 and R3 are each independently selected from C 14 -C 22 Monounsaturated alkenyl.
4. The use according to claim 1, wherein R1, R2 and R3 are each independently selected from C 16 -C 20 Monounsaturated alkenyl.
5. The use according to claim 1, wherein the compound shown in formula I comprises triolein.
6. The use according to claim 1, wherein the triglyceride compound is derived from naturally occurring oil, naturally occurring fat, semi-synthetic triglyceride or synthetic triglyceride.
7. The use according to claim 1, wherein the composition comprises: A pharmaceutical composition, a health product composition, a food composition, or a dietary supplement composition.
8. The use according to claim 1, wherein the composition can be administered orally, intravenously, subcutaneously, intramuscularly, nasally, through bronchoscopy or by aerosol inhalation.
9. The use according to any one of claims 1 to 8, wherein the composition is used to reverse epithelial-mesenchymal transition.
10. The use according to any one of claims 1 to 8, wherein the composition is used to alleviate fibrosis symptoms.
